Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03154619 · ClinicalTrials.gov registry record · Phase 2
Efficacy of TR 987, Beta-1,3-1,6-D-glucan, in the Treatment of Chronic Venous Insufficiency Ulcers
A Phase 2 study of Venous Leg Ulcer, sponsored by SerenaGroup.
- Active
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 9
- Study locations
NCT03154619: Active Phase 2 study of Venous Leg Ulcer, sponsored by SerenaGroup.
NCT03154619 is a Phase 2 study of Venous Leg Ulcer that is active but no longer recruiting, run by SerenaGroup. The registered enrollment target is 80 participants, below the 243-participant average among 35 other Venous Leg Ulcer trials with a reported enrollment target (67% lower). The trial reports 9 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03154619, a Phase 2 study of Venous Leg Ulcer, is active but no longer recruiting, sponsored by SerenaGroup.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 9
- Study locations
Study Summary
The safety and efficacy of beta glucan products, and specifically TR 987, in the treatment of chronic venous insufficiency ulcers has been established. This study is designed to determine the most efficient method of treatment.
Conditions Studied
Interventions
- DRUG Placebo gel
- DRUG 0.1% TR 987
Study Locations (9)
Pennsylvania
- The Foot and Ankle Wellness Center - Ford City
- Armstrong County Memorial Hospital - Kittanning
- SerenaGroup Research Institute - Pittsburgh
- Martin Foot and Ankle - York
Florida
- Barry University Clinical Research - North Miami Beach
- Royal Research Corp - Pembroke Pines
California
- New Hope Podiatry Clinic - Los Angeles
New Jersey
- Deborah Heart and Lung Center - Browns Mills
Ohio
- Cleveland Foot and Ankle Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2016-11 |
| Est. Completion | 2021-04-01 |
| Phase | Phase 2 |
What the registry record for NCT03154619 still lists
NCT03154619 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 243-participant average among 35 other Venous Leg Ulcer trials with a reported enrollment target (67% lower).
The record links to 1 condition, with Venous Leg Ulcer appearing as the primary indexed condition, and to 2 interventions - of which Placebo gel is the first listed.
NCT03154619 lists 9 locations in 5 states (Pennsylvania, Florida, California).
Frequently Asked Questions
What is clinical trial NCT03154619 about?
NCT03154619 is a clinical study titled "Efficacy of TR 987, Beta-1,3-1,6-D-glucan, in the Treatment of Chronic Venous Insufficiency Ulcers". The safety and efficacy of beta glucan products, and specifically TR 987, in the treatment of chronic venous insufficiency ulcers has been established. This study is designed to determine the most efficient method of treatment.
What is the current status of trial NCT03154619?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2016-11. Estimated completion is 2021-04-01.
What conditions does trial NCT03154619 study?
This clinical trial studies the following conditions: Venous Leg Ulcer.
What interventions are being tested in trial NCT03154619?
The interventions under investigation include: Placebo gel (DRUG), 0.1% TR 987 (DRUG).
Who is sponsoring clinical trial NCT03154619?
This trial is sponsored by SerenaGroup, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03154619 being conducted?
This trial has 9 study locations across California, Florida, New Jersey, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Venous Leg Ulcer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03154619's enrollment target sits among peer trials
80 26th of 35 higher than 10 of 35 other Venous Leg Ulcer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Venous Leg Ulcer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dermacyte® Amniotic Wound Care Liquid for the Treatment of Non-Healing Venous Stasis Ulcers
RECRUITING · Phase 2
-
A Study to Evaluate the Safety and the Efficacy of EscharEx (EX-02 Formulation) in Debridement of Venous Leg Ulcers
COMPLETED · Phase 2
-
Dose-response Relationship Study of S42909 on Leg Ulcer Healing
COMPLETED · Phase 2
-
Study Assessing Complete Wound Healing by Comparing Surgenex® PelloGraft in Treating DFU and SanoGraft® in Treating VLU to SOC
RECRUITING · NA
-
Human Amniotic Membrane On Venous Leg Ulcers In an Elderly Population
RECRUITING · NA
-
A Clinical Investigation to Follow the Progress of Exuding Chronic Wounds Using Mepilex® Up as the Primary Dressing.
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia